EA201291065A1 - Антитела против vla-4 - Google Patents
Антитела против vla-4Info
- Publication number
- EA201291065A1 EA201291065A1 EA201291065A EA201291065A EA201291065A1 EA 201291065 A1 EA201291065 A1 EA 201291065A1 EA 201291065 A EA201291065 A EA 201291065A EA 201291065 A EA201291065 A EA 201291065A EA 201291065 A1 EA201291065 A1 EA 201291065A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibodies against
- against vla
- vla
- antibodies
- fragments
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Plant Pathology (AREA)
Abstract
Изобретение относится к антителам, связывающимся с белком альфа-4, и их фрагментам.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32494410P | 2010-04-16 | 2010-04-16 | |
PCT/US2011/032641 WO2011130603A2 (en) | 2010-04-16 | 2011-04-15 | Anti-vla-4 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201291065A1 true EA201291065A1 (ru) | 2013-03-29 |
Family
ID=44628095
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201291065A EA201291065A1 (ru) | 2010-04-16 | 2011-04-15 | Антитела против vla-4 |
Country Status (24)
Country | Link |
---|---|
US (5) | US20140161794A1 (ru) |
EP (4) | EP3466977B1 (ru) |
JP (5) | JP6085554B2 (ru) |
KR (1) | KR20130066584A (ru) |
CN (1) | CN103038257A (ru) |
AU (1) | AU2011239512B2 (ru) |
BR (1) | BR112012026403B1 (ru) |
CA (1) | CA2794863C (ru) |
CY (2) | CY1119154T1 (ru) |
DK (3) | DK3202789T3 (ru) |
EA (1) | EA201291065A1 (ru) |
ES (3) | ES2912934T3 (ru) |
HR (2) | HRP20171045T1 (ru) |
HU (2) | HUE050858T2 (ru) |
LT (2) | LT3202789T (ru) |
ME (2) | ME02793B (ru) |
MX (1) | MX340683B (ru) |
NZ (1) | NZ602676A (ru) |
PL (3) | PL3202789T3 (ru) |
PT (2) | PT2558499T (ru) |
RS (2) | RS60897B1 (ru) |
SG (3) | SG10202112020VA (ru) |
SI (2) | SI2558499T1 (ru) |
WO (1) | WO2011130603A2 (ru) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3466977B1 (en) | 2010-04-16 | 2022-01-05 | Biogen MA Inc. | Anti-vla-4 antibodies |
CN105658667A (zh) * | 2013-07-05 | 2016-06-08 | 比奥根Ma公司 | 用于治疗中风的组合物和方法 |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
MX2018003689A (es) * | 2015-09-29 | 2018-04-30 | Celgene Corp | Proteinas de union a pd-1 y metodos para usarlas. |
EP3515943A4 (en) | 2016-09-19 | 2020-05-06 | Celgene Corporation | METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS |
KR102257154B1 (ko) * | 2016-09-19 | 2021-05-28 | 셀진 코포레이션 | Pd-1 결합 단백질을 사용하는 면역 질환의 치료 방법 |
WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
JP2019136399A (ja) * | 2018-02-14 | 2019-08-22 | 株式会社三洋物産 | 遊技機 |
JP2019136398A (ja) * | 2018-02-14 | 2019-08-22 | 株式会社三洋物産 | 遊技機 |
JP7457661B2 (ja) * | 2018-06-04 | 2024-03-28 | バイオジェン・エムエイ・インコーポレイテッド | 低減したエフェクター機能を有する抗vla-4抗体 |
AU2021274151A1 (en) | 2020-05-19 | 2023-02-02 | Janssen Biotech, Inc. | Compositions comprising a T cell redirection therapeutic and a VLA-4 adhesion pathway inhibitor |
BR102020016890A2 (pt) | 2020-08-19 | 2022-05-03 | Fundação Oswaldo Cruz | Proteina, polinucleotídeo, vetor, célula hospedeira, composição, método para tratar uma doença, método in vitro para prognosticar esclerose múltipla, e, uso de uma proteína ou composição |
AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
MX2023013791A (es) | 2021-05-18 | 2024-02-13 | Janssen Biotech Inc | Composiciones que comprenden una terapéutica de redirección de células t y una terapéutica anti-cd44. |
Family Cites Families (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
JPS6081397A (ja) | 1983-10-06 | 1985-05-09 | 荒川化学工業株式会社 | 中性抄紙方法 |
US4494880A (en) | 1984-03-14 | 1985-01-22 | Su Wen Kuang | Foldable clock dial |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
EP0216846B2 (en) | 1985-04-01 | 1995-04-26 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
NZ215865A (en) | 1985-04-22 | 1988-10-28 | Commw Serum Lab Commission | Method of determining the active site of a receptor-binding analogue |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
HU196394B (en) | 1986-06-27 | 1988-11-28 | Richter Gedeon Vegyeszet | Process for preparing 2-halogenated ergoline derivatives |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
SE461013B (sv) | 1988-02-11 | 1989-12-18 | Christian Wesslau | Farmaceutisk komposition verksam mot lungobstruktioner bestaaende av en betaadrenerg antagonist och ett tyroideahormon |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6307025B1 (en) | 1989-04-28 | 2001-10-23 | Biogen, Inc. | VCAM fusion proteins and DNA coding therefor |
US5272263A (en) | 1989-04-28 | 1993-12-21 | Biogen, Inc. | DNA sequences encoding vascular cell adhesion molecules (VCAMS) |
US5217870A (en) | 1989-04-28 | 1993-06-08 | Biogen, Inc. | Monoclonal antibodies against CDX |
US6033665A (en) | 1989-09-27 | 2000-03-07 | Elan Pharmaceuticals, Inc. | Compositions and methods for modulating leukocyte adhesion to brain endothelial cells |
US5260210A (en) | 1989-09-27 | 1993-11-09 | Rubin Lee L | Blood-brain barrier model |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5192746A (en) | 1990-07-09 | 1993-03-09 | Tanabe Seiyaku Co., Ltd. | Cyclic cell adhesion modulation compounds |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
GB9019812D0 (en) | 1990-09-11 | 1990-10-24 | Scotgen Ltd | Novel antibodies for treatment and prevention of infection in animals and man |
EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
US5871734A (en) | 1992-01-13 | 1999-02-16 | Biogen, Inc. | Treatment for asthma with VLA-4 blocking agents |
WO1993013798A1 (en) | 1992-01-13 | 1993-07-22 | Biogen, Inc. | Treatment for asthma |
US5932214A (en) | 1994-08-11 | 1999-08-03 | Biogen, Inc. | Treatment for inflammatory bowel disease with VLA-4 blockers |
JPH07506566A (ja) | 1992-02-12 | 1995-07-20 | バイオゲン インコーポレイテッド | 炎症性胃腸病の処置 |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
USRE40811E1 (en) | 1992-11-13 | 2009-06-30 | Board Of Regents Of The University Of Washington | Peripheralization of hematopoietic stem cells |
ES2137354T3 (es) | 1993-01-12 | 1999-12-16 | Biogen Inc | Moleculas de anticuerpo anti-vla4 recombinante. |
EP0682525A1 (en) | 1993-02-08 | 1995-11-22 | The Syntex-Synergen Neuroscience Joint Venture | Methods for treating amyotrophic lateral sclerosis with cntf |
ES2114183T5 (es) | 1993-02-09 | 2006-06-16 | Biogen Idec Ma, Inc. | Anticuerpo para el tratamiento de la diabetes dependiente de la insulina. |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US6432404B1 (en) | 1993-12-23 | 2002-08-13 | Icos Corporation | Methods of inhibiting locomotor damage following spinal cord injury with α D-specific antibodies |
EP0804237B8 (en) | 1994-01-25 | 2006-11-08 | Elan Pharmaceuticals, Inc. | Humanized antibodies against leukocyte adhesion molecule vla-4 |
US5840299A (en) * | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
US5672622A (en) | 1994-04-21 | 1997-09-30 | Berlex Laboratories, Inc. | Treatment of multiple sclerosis |
SE504751C2 (sv) | 1994-06-30 | 1997-04-21 | Lars Fredriksson | Kopplingslänk |
US5498156A (en) | 1994-09-02 | 1996-03-12 | Ipsco Enterprises Inc. | Dual-purpose guide and drum cleaner for Steckel mill coiler furnace |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
DE19541844C1 (de) | 1995-11-09 | 1997-07-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung |
DE69721548T2 (de) | 1996-02-09 | 2004-04-01 | Abbott Laboratories(Bermuda)Ltd. | HUMANE ANTIKÖRPER WELCHE AN HUMANEN TNFalpha BINDEN |
CA2261848C (en) | 1996-07-25 | 2006-10-24 | Biogen, Inc. | Cell adhesion inhibitors |
US7361331B2 (en) | 1996-10-18 | 2008-04-22 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food | Plant bioreactors |
PT1500329E (pt) | 1996-12-03 | 2012-06-18 | Amgen Fremont Inc | Anticorpos humanos que se ligam especificamente ao tnf alfa humano |
US6890526B2 (en) | 1997-05-06 | 2005-05-10 | Vanderbilt University | Methods and reagents for the treatment of multiple sclerosis |
IL133635A0 (en) | 1997-07-31 | 2001-04-30 | Elan Pharm Inc | Benzyl compounds which inhibit leukocyte adhesion mediated by vla-4 |
US6153653A (en) | 1997-11-26 | 2000-11-28 | Protarga, Inc. | Choline compositions and uses thereof |
AU2203199A (en) | 1997-12-30 | 1999-07-19 | Bioabsorbable Concepts, Inc. | Tetracycline and/or tetracycline derivative(s) for treating, suppressing and preventing of cerebrovascular diseases of nervous system |
MXPA00011774A (es) | 1998-05-28 | 2002-10-17 | Biogen Inc | Un nuevo inhibidor vla-4: ome pupa-v. |
US7232830B2 (en) | 1998-06-26 | 2007-06-19 | Elaine A Delack | Method for treatment of neurodegenerative diseases and effects of aging |
EA004270B1 (ru) * | 1998-09-14 | 2004-02-26 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | Способы лечения множественной миеломы и индуцированной миеломой резорбции костей с помощью антагонистов интегрина |
US6355623B2 (en) | 1998-09-24 | 2002-03-12 | Hopital-Sainte-Justine | Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage |
DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
EP1119368A2 (en) | 1999-03-03 | 2001-08-01 | Biogen, Inc. | Methods of modulating lipid metabolism and storage |
AU2446801A (en) | 1999-12-23 | 2001-07-03 | Ancile Pharmaceuticals, Inc. | Treatment for inflammatory bowel disease (ibd) and related conditions |
WO2001055112A1 (en) | 2000-01-27 | 2001-08-02 | American Cyanamid Company | Method for preparing alpha-sulfonyl hydroxamic acid derivatives |
CA2404488C (en) | 2000-03-31 | 2012-01-10 | The Scripps Research Institute | Human aminoacyl-trna synthetase polypeptides useful for the regulation of angiogenesis |
US8288322B2 (en) | 2000-04-17 | 2012-10-16 | Dyax Corp. | Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries |
US6537243B1 (en) | 2000-10-12 | 2003-03-25 | Abbott Laboratories | Device and method for obtaining interstitial fluid from a patient for diagnostic tests |
CN1541106A (zh) | 2001-06-11 | 2004-10-27 | 转新疗法公司 | 用维生素b12和治疗剂联合治疗病毒性、增殖性和炎性疾病的方法 |
EP1581119B1 (en) | 2001-12-17 | 2013-01-30 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of inflammatory bowel disease |
US20040203031A1 (en) | 2002-04-03 | 2004-10-14 | University Of Pennsylvania | Methods for determining drug responsiveness |
EP2532241B1 (en) | 2002-02-15 | 2016-05-11 | Cornell Research Foundation, Inc. | Myelination of congenitally dysmyelinated forebrains using oligodendrocyte progenitor cells |
EP2360185A3 (en) | 2002-02-25 | 2012-01-11 | Elan Pharmaceuticals Inc. | Administration of agents for the treatment of inflammation |
WO2003074679A2 (en) * | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
EP3502133A1 (en) | 2002-09-27 | 2019-06-26 | Xencor, Inc. | Optimized fc variants and methods for their generation |
AU2003284246A1 (en) | 2002-10-16 | 2004-05-04 | Samuel F. Hunter | Method for treatment of demyelinating central nervous system disease using gm-csf |
JP4690046B2 (ja) | 2002-11-22 | 2011-06-01 | 中外製薬株式会社 | 病巣組織に対する抗体 |
UY28170A1 (es) | 2003-01-24 | 2004-07-30 | Elan Pharm Inc | Preparacion y tratamiento para las enfermedades desmielinizantes y paralisis mediante la aplicacion de agentes remielinizantes. |
HUE051878T2 (hu) | 2003-02-10 | 2021-03-29 | Biogen Ma Inc | Immunglobulin készítmény és annak elõállítási módszere |
US20050074443A1 (en) | 2003-10-03 | 2005-04-07 | Treadwell Benjamin V. | Methods of attenuating autoimmune disease and compositions useful therefor |
AU2004290070A1 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto |
WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
MY162179A (en) | 2004-04-01 | 2017-05-31 | Elan Pharm Inc | Steroid sparing agents and methods of using same |
BRPI0508762A (pt) | 2004-04-16 | 2007-08-14 | Genentech Inc | método de aumento do esgotamento de células b em mamìferos, método de aumento da eficácia do esgotamento de células b, método de tratamento de malignidade ou neoplasma de células b, método de alìvio de disfunção autoimunológica regulada por células b, método de esgotamento das células b e composição |
CA2478458A1 (en) | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
SI1784426T1 (sl) | 2004-09-03 | 2012-03-30 | Genentech Inc | Humanizirani antagonisti proti beta in njihove uporabe |
CN103169965A (zh) * | 2004-11-19 | 2013-06-26 | 比奥根艾迪克Ma公司 | 治疗多发性硬化 |
NZ581497A (en) | 2004-12-03 | 2012-07-27 | Biogen Idec Inc | Delaying or preventing onset of multiple sclerosis by vla-4 ginding antibody |
US7678371B2 (en) | 2005-03-04 | 2010-03-16 | Biogen Idec Ma Inc. | Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues |
DE602006019731D1 (de) | 2005-06-09 | 2011-03-03 | Ucb Pharma Sa | 2,6-chinolinderivate sowie verfahren zu ihrer herstellung und verwendung als arzneimittel |
EP2004695A2 (en) | 2005-07-08 | 2008-12-24 | Xencor, Inc. | Optimized anti-ep-cam antibodies |
JP5496658B2 (ja) | 2006-05-25 | 2014-05-21 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 脳卒中を処置する方法 |
WO2008021954A2 (en) | 2006-08-09 | 2008-02-21 | Biogen Idec Ma Inc. | Method for distribution of a drug |
US8771689B2 (en) | 2006-12-11 | 2014-07-08 | The Board Of Trustees Of The Leland Stanford Junior University | Alpha B-crystallin as a therapy for ischemia or inflammation |
US8931218B2 (en) | 2007-04-19 | 2015-01-13 | Oldcastle Building Products, Inc. | Modular brick or block outdoor structures |
KR20100021601A (ko) | 2007-05-14 | 2010-02-25 | 바이오겐 아이덱 엠에이 인코포레이티드 | 단일-쇄 Fc(ScFc) 부분, 이를 포함하는 결합 폴리펩타이드, 및 이에 관련된 방법 |
EP3461500A1 (en) | 2007-06-14 | 2019-04-03 | Biogen MA Inc. | Natalizumab antibody formulations |
US20090004189A1 (en) | 2007-06-18 | 2009-01-01 | Genentech, Inc. | Biological markers predictive of rheumatoid arthritis response to b-cell antagonists |
DE102007049542A1 (de) | 2007-10-16 | 2009-04-23 | Neue Magnetodyn Gmbh | Implantierbare Vorrichtung, System zum Erzeugen lokalisierter elektromagnetischer Felder im Bereich eines Implantats und Spulenanordnung |
EP2050462A1 (en) | 2007-10-18 | 2009-04-22 | PAION Deutschland GmbH | Improved treatment of stroke patients |
EP3466977B1 (en) * | 2010-04-16 | 2022-01-05 | Biogen MA Inc. | Anti-vla-4 antibodies |
EP2769223A1 (en) | 2011-10-17 | 2014-08-27 | Westfälische Wilhelms-Universität Münster | Assessment of pml risk and methods based thereon |
-
2011
- 2011-04-15 EP EP18205524.4A patent/EP3466977B1/en active Active
- 2011-04-15 ME MEP-2017-148A patent/ME02793B/me unknown
- 2011-04-15 SG SG10202112020VA patent/SG10202112020VA/en unknown
- 2011-04-15 RS RS20200950A patent/RS60897B1/sr unknown
- 2011-04-15 NZ NZ602676A patent/NZ602676A/en unknown
- 2011-04-15 SG SG10201502967RA patent/SG10201502967RA/en unknown
- 2011-04-15 ES ES18205524T patent/ES2912934T3/es active Active
- 2011-04-15 DK DK17163411.6T patent/DK3202789T3/da active
- 2011-04-15 LT LTEP17163411.6T patent/LT3202789T/lt unknown
- 2011-04-15 ME MEP-2020-168A patent/ME03813B/me unknown
- 2011-04-15 PT PT117301200T patent/PT2558499T/pt unknown
- 2011-04-15 EA EA201291065A patent/EA201291065A1/ru unknown
- 2011-04-15 DK DK11730120.0T patent/DK2558499T3/en active
- 2011-04-15 DK DK18205524.4T patent/DK3466977T3/da active
- 2011-04-15 MX MX2012012010A patent/MX340683B/es active IP Right Grant
- 2011-04-15 CA CA2794863A patent/CA2794863C/en active Active
- 2011-04-15 JP JP2013505169A patent/JP6085554B2/ja active Active
- 2011-04-15 US US13/641,199 patent/US20140161794A1/en not_active Abandoned
- 2011-04-15 KR KR1020127027585A patent/KR20130066584A/ko not_active Application Discontinuation
- 2011-04-15 HU HUE17163411A patent/HUE050858T2/hu unknown
- 2011-04-15 PL PL17163411T patent/PL3202789T3/pl unknown
- 2011-04-15 PL PL11730120T patent/PL2558499T3/pl unknown
- 2011-04-15 LT LTEP11730120.0T patent/LT2558499T/lt unknown
- 2011-04-15 EP EP11730120.0A patent/EP2558499B1/en active Active
- 2011-04-15 PL PL18205524T patent/PL3466977T3/pl unknown
- 2011-04-15 SG SG2012071999A patent/SG184318A1/en unknown
- 2011-04-15 AU AU2011239512A patent/AU2011239512B2/en active Active
- 2011-04-15 SI SI201131238T patent/SI2558499T1/sl unknown
- 2011-04-15 EP EP21218415.4A patent/EP4032912A1/en active Pending
- 2011-04-15 ES ES17163411T patent/ES2805873T3/es active Active
- 2011-04-15 PT PT171634116T patent/PT3202789T/pt unknown
- 2011-04-15 SI SI201131902T patent/SI3202789T1/sl unknown
- 2011-04-15 HU HUE11730120A patent/HUE035098T2/en unknown
- 2011-04-15 BR BR112012026403-6A patent/BR112012026403B1/pt active IP Right Grant
- 2011-04-15 RS RS20170701A patent/RS56082B1/sr unknown
- 2011-04-15 WO PCT/US2011/032641 patent/WO2011130603A2/en active Application Filing
- 2011-04-15 ES ES11730120.0T patent/ES2633105T3/es active Active
- 2011-04-15 EP EP17163411.6A patent/EP3202789B1/en active Active
- 2011-04-15 CN CN2011800296749A patent/CN103038257A/zh active Pending
-
2017
- 2017-01-30 JP JP2017014410A patent/JP6525440B2/ja active Active
- 2017-07-10 HR HRP20171045TT patent/HRP20171045T1/hr unknown
- 2017-07-10 CY CY20171100728T patent/CY1119154T1/el unknown
- 2017-12-12 US US15/838,884 patent/US10335485B2/en active Active
-
2018
- 2018-05-15 JP JP2018093927A patent/JP2018123165A/ja not_active Withdrawn
-
2019
- 2019-06-14 US US16/441,974 patent/US11083791B2/en active Active
- 2019-10-09 JP JP2019185798A patent/JP2020019811A/ja active Pending
-
2020
- 2020-06-02 CY CY20201100516T patent/CY1122978T1/el unknown
- 2020-08-03 HR HRP20201219TT patent/HRP20201219T1/hr unknown
-
2021
- 2021-07-02 US US17/366,903 patent/US11571477B2/en active Active
-
2022
- 2022-07-22 JP JP2022117076A patent/JP2022141875A/ja active Pending
-
2023
- 2023-02-06 US US18/165,146 patent/US20240100155A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201291065A1 (ru) | Антитела против vla-4 | |
CY1120471T1 (el) | Αντισωματα κατα του cd70 | |
EA201791693A1 (ru) | Гетеродимерные иммуноглобулины | |
EA201891093A1 (ru) | Антитела, специфически связывающие pd-1, и их применение | |
EA201400875A1 (ru) | Антитела к cd47 и способы их применения | |
EP4356927A3 (en) | Antibody based reagents that specifically recognize toxic oligomeric forms of tau | |
EA201491811A1 (ru) | АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ | |
EA201491214A1 (ru) | Композиции и способы применения антител, нацеленных на фактор p | |
EA202091315A2 (ru) | Антитела человека, связывающиеся с g-белком rsv | |
EA201790757A1 (ru) | Связывающие антиген cd27l белки | |
CR20140585A (es) | Proteinas de union a antigeno st2 | |
MX2019007921A (es) | Nuevos agentes de union a ha. | |
EA201690314A1 (ru) | Анти-garp-белок и его применения | |
EA201400579A1 (ru) | Антитела к il-36r | |
MX2014009289A (es) | Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer. | |
TR201817932T4 (tr) | Staphylococcus aureus alfa toksi̇ni̇ni̇ spesi̇fi̇k olarak bağlayan anti̇korlar ve kullanim yöntemleri̇ | |
EA201390785A1 (ru) | Антитела, обладающие низкой аффинностью к рецепторам гематоэнцефалического барьера, и их применения | |
EA201491541A1 (ru) | АНТИТЕЛА ПРОТИВ ИНТЕГРИНОВ αvβ6 И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ | |
EA201690310A1 (ru) | Антитела, связывающие cd27 человека, и их применение | |
EA201390929A1 (ru) | Антитела к pcsk9 и способы их применения | |
EA201201016A1 (ru) | Антидоты антикоагулянтов | |
EA201491357A1 (ru) | Анти-lrp5 антитела и способы их применения | |
EA201400447A1 (ru) | АНТИТЕЛА К CD1d | |
TR201903403T4 (tr) | İmmünoglobulin preparatı. | |
PH12015500752A1 (en) | Her3 antigen binding proteins binding to the beta-hairpin of her3 |